Literature DB >> 25762405

Homogentisate 1,2 dioxygenase is expressed in brain: implications in alkaptonuria.

Giulia Bernardini1, Marcella Laschi, Michela Geminiani, Daniela Braconi, Elisa Vannuccini, Pietro Lupetti, Fabrizio Manetti, Lia Millucci, Annalisa Santucci.   

Abstract

Alkaptonuria is an ultra-rare autosomal recessive disease developed from the lack of homogentisate 1,2-dioxygenase (HGD) activity, causing an accumulation in connective tissues of homogentisic acid (HGA) and its oxidized derivatives in polymerized form. The deposition of ochronotic pigment has been so far attributed to homogentisic acid produced by the liver, circulating in the blood, and accumulating locally. In the present paper, we report the expression of HGD in the brain. Mouse and human brain tissues were positively tested for HGD gene expression by western blotting. Furthermore, HGD expression was confirmed in human neuronal cells that also revealed the presence of six HGD molecular species. Moreover, once cultured in HGA excess, human neuronal cells produced ochronotic pigment and amyloid. Our findings indicate that alkaptonuric brain cells produce the ochronotic pigment in loco and this may contribute to induction of neurological complications.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25762405     DOI: 10.1007/s10545-015-9829-5

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  33 in total

1.  Dura mater involvement in ochronosis (alkaptonuria).

Authors:  W Liu; R A Prayson
Journal:  Arch Pathol Lab Med       Date:  2001-07       Impact factor: 5.534

2.  Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model.

Authors:  Laura Tinti; Adriano Spreafico; Daniela Braconi; Lia Millucci; Giulia Bernardini; Federico Chellini; Giovanni Cavallo; Enrico Selvi; Mauro Galeazzi; Roberto Marcolongo; James A Gallagher; Annalisa Santucci
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

3.  Generation of high-quality protein extracts from formalin-fixed, paraffin-embedded tissues.

Authors:  Maria Filippa Addis; Alessandro Tanca; Daniela Pagnozzi; Salvatore Crobu; Giuseppe Fanciulli; Paolo Cossu-Rocca; Sergio Uzzau
Journal:  Proteomics       Date:  2009-08       Impact factor: 3.984

4.  A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems.

Authors:  Trevor F Cox; Lakshminarayan Ranganath
Journal:  J Inherit Metab Dis       Date:  2011-07-09       Impact factor: 4.982

5.  Proteomic and redox-proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes.

Authors:  Daniela Braconi; Marcella Laschi; Adam M Taylor; Giulia Bernardini; Adriano Spreafico; Laura Tinti; James A Gallagher; Annalisa Santucci
Journal:  J Cell Biochem       Date:  2010-11-01       Impact factor: 4.429

Review 6.  [Parkinson disease and alkaptonuria: fortuitous association or striatonigral ochronosis?].

Authors:  R Aquaron; G Fayet; C Barthet; S Désiré; F Viallet
Journal:  Rev Neurol (Paris)       Date:  1995-01       Impact factor: 2.607

7.  Diagnosis of secondary amyloidosis in alkaptonuria.

Authors:  Lia Millucci; Lorenzo Ghezzi; Giulia Bernardini; Daniela Braconi; Pietro Lupetti; Federico Perfetto; Maurizio Orlandini; Annalisa Santucci
Journal:  Diagn Pathol       Date:  2014-09-26       Impact factor: 2.644

8.  BioGPS and MyGene.info: organizing online, gene-centric information.

Authors:  Chunlei Wu; Ian Macleod; Andrew I Su
Journal:  Nucleic Acids Res       Date:  2012-11-21       Impact factor: 16.971

9.  Alkaptonuria is a novel human secondary amyloidogenic disease.

Authors:  Lia Millucci; Adriano Spreafico; Laura Tinti; Daniela Braconi; Lorenzo Ghezzi; Eugenio Paccagnini; Giulia Bernardini; Loredana Amato; Marcella Laschi; Enrico Selvi; Mauro Galeazzi; Alessandro Mannoni; Maurizio Benucci; Pietro Lupetti; Federico Chellini; Maurizio Orlandini; Annalisa Santucci
Journal:  Biochim Biophys Acta       Date:  2012-07-28

10.  Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria.

Authors:  Adriano Spreafico; Lia Millucci; Lorenzo Ghezzi; Michela Geminiani; Daniela Braconi; Loredana Amato; Federico Chellini; Bruno Frediani; Elena Moretti; Giulia Collodel; Giulia Bernardini; Annalisa Santucci
Journal:  Rheumatology (Oxford)       Date:  2013-05-23       Impact factor: 7.580

View more
  9 in total

1.  Progress in Alkaptonuria--are we near to an effective therapy?

Authors:  L R Ranganath; O G Timmis; J A Gallagher
Journal:  J Inherit Metab Dis       Date:  2015-09       Impact factor: 4.982

Review 2.  Metabolomic and Lipidomic Biomarkers for Premalignant Liver Disease Diagnosis and Therapy.

Authors:  Diren Beyoğlu; Jeffrey R Idle
Journal:  Metabolites       Date:  2020-01-28

3.  Impact of Nitisinone on the Cerebrospinal Fluid Metabolome of a Murine Model of Alkaptonuria.

Authors:  Andrew S Davison; Brendan P Norman; Hazel Sutherland; Anna M Milan; James A Gallagher; Jonathan C Jarvis; Lakshminarayan R Ranganath
Journal:  Metabolites       Date:  2022-05-25

Review 4.  Amyloidosis in alkaptonuria.

Authors:  Lia Millucci; Daniela Braconi; Giulia Bernardini; Pietro Lupetti; Josef Rovensky; Lakshminaryan Ranganath; Annalisa Santucci
Journal:  J Inherit Metab Dis       Date:  2015-04-14       Impact factor: 4.982

5.  Reduced primary cilia length and altered Arl13b expression are associated with deregulated chondrocyte Hedgehog signaling in alkaptonuria.

Authors:  Stephen D Thorpe; Silvia Gambassi; Clare L Thompson; Charmilie Chandrakumar; Annalisa Santucci; Martin M Knight
Journal:  J Cell Physiol       Date:  2017-03-31       Impact factor: 6.384

6.  Conditional targeting in mice reveals that hepatic homogentisate 1,2-dioxygenase activity is essential in reducing circulating homogentisic acid and for effective therapy in the genetic disease alkaptonuria.

Authors:  Juliette H Hughes; Ke Liu; Antonius Plagge; Peter J M Wilson; Hazel Sutherland; Brendan P Norman; Andrew T Hughes; Craig M Keenan; Anna M Milan; Takao Sakai; Lakshminarayan R Ranganath; James A Gallagher; George Bou-Gharios
Journal:  Hum Mol Genet       Date:  2019-12-01       Impact factor: 6.150

Review 7.  Alkaptonuria: Current Perspectives.

Authors:  Andrea Zatkova; Lakshminarayan Ranganath; Ludevit Kadasi
Journal:  Appl Clin Genet       Date:  2020-01-23

8.  Towards a Precision Medicine Approach Based on Machine Learning for Tailoring Medical Treatment in Alkaptonuria.

Authors:  Ottavia Spiga; Vittoria Cicaloni; Anna Visibelli; Alessandro Davoli; Maria Ausilia Paparo; Maurizio Orlandini; Barbara Vecchi; Annalisa Santucci
Journal:  Int J Mol Sci       Date:  2021-01-26       Impact factor: 5.923

9.  Expression of tyrosine pathway enzymes in mice demonstrates that homogentisate 1,2-dioxygenase deficiency in the liver is responsible for homogentisic acid-derived ochronotic pigmentation.

Authors:  Peter J M Wilson; Lakshminarayan R Ranganath; George Bou-Gharios; James A Gallagher; Juliette H Hughes
Journal:  JIMD Rep       Date:  2020-11-12
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.